GlobeNewswire EN Nachrichten

 

- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD -...

CALGARY, Alberta, Feb. 22, 2026 (GLOBE NEWSWIRE) -- (“Canacol” or the “Company”) announces a leadership change and the appointment of an independent director to the board of directors (the “Board”). The Board believes that these changes will position the Company for success in the next phase of its restructuring by adding substantial restructuring experience to the Board....

LONDON, Feb. 22, 2026 (GLOBE NEWSWIRE) -- nVent Electric plc (NYSE: NVT) (“nVent”), a global leader in electrical connection and protection solutions, today announced that it is postponing its Investor Day, originally scheduled for February 24, 2026, due to a state of emergency declared for the New York metropolitan area ahead of a major winter storm, expected to bring blizzard conditions....

ZUG, Switzerland, February 22, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces topline results from the S-OLARIS Phase 2 trial of SLK in patients with radiographic and non-radiographic axSpA and announces its financial results for the fourth quarter and year ended December 31, 2025. An Investor Day webcast has been confirmed for February 23, 2026, 8.00 – 9.30 am EST (2:00 – 3.30pm CET), including an open Q&A session....

Press ReleaseVELIZY-VILLACOUBLAY, France — February 21, 2026...

VANCOUVER, British Columbia, Feb. 21, 2026 (GLOBE NEWSWIRE) -- ANORTECH INC. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) has granted incentive stock options under the Company's stock option plan to directors, employees and consultants to purchase a total of 5,150,000 shares at a price of $0.10 per share. The options vest over 18 months and have a term of five years, subject to the policies of the TSX Venture Exchange....

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026...

Proposed $1.0 Million Convertible Debenture and Warrant Financing and Concurrent Common Share Private Placement Up to $1.0 Million Intended to Support Near-Term Operations...

VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) ("VERSES" or the "Company"), a cognitive computing company pioneering next-generation agentic software systems today announced that it has filed its Quarterly Report on Form 10-Q (“Quarterly Report”) for the three months and nine months ended December 31, 2025, with the U.S. Securities and Exchange Commission (“SEC”)....

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- K2 Capital Acquisition Corp. (the "Company") today announced that, commencing on February 25, 2026, holders of the 13,800,000 units (the “Units”) sold in the Company's initial public offering (the “Offering”), including Units sold upon full exercise of the underwriters' over-allotment option, may elect to separately trade the Class A ordinary shares and rights included in the Units. Any Units not separated will continue to trade on the NASDAQ Global Market (“NASDAQ”) under the symbol “KTWOU.” Any underlying Class A ordinary shares and rights that are separated will trade on the NASDAQ under the symbols “KTWO” and “KTWOR,” respectively. Holders of Units will need to have their brokers contact the Company's transfer agent, VStock Transfer, in order to separate the holders' Units into Class A ordinary shares and rights....

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES...

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds ("PsyLabs") has exercised its rights under a previously disclosed put option agreement (the "Put Option Agreement"), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement....

SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on February 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 3,600 shares of Iovance's common stock to two new, non-executive employees....

TORONTO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced on February 17, 2026 that it would be holding its fourth quarter conference call on March 10, 2026 at 8:00 am. Constellation has changed the date of the conference call to March 9, 2026 at 8:30 am....

Equinox Gold has filed its audited financial statements and MD&A for the three months and year ended December 31, 2025....

GRIMSBY, Ontario, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Andrew Peller Limited (TSX: ADW.A / ADW.B) (“APL” or the “Company”) announced today that W. James Westlake has resigned from the Company's board of directors to focus on other commitments....

HERNDON, Va., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Navient (Nasdaq: NAVI) announced that its board of directors approved a 2026 first quarter dividend of $0.16 per share on the company's common stock....

NEWMARKET, Ontario, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AirBoss of America Corp. (TSX: BOS) (OTCQX:ABSSF) (the “Company” or “AirBoss”) today announced that it will release its fourth quarter and unaudited full year 2025 results after markets close on March 4, 2026. The release will be followed by a conference call to discuss the results on Thursday, March 5, 2026, at 9:00 am ET. The Company will file its audited annual consolidated financial statements and related management's discussion and analysis for the year ended December 31, 2025 following the conclusion of the audit and in accordance with applicable securities laws....

DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (“MVPHS”) of $15,000,000, based on Nasdaq's review of the Company's MVPHS for the last 30 consecutive business days....

WEST ORANGE, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- BEL FUSE INC. (NASDAQ:BELFA) and (NASDAQ:BELFB) today announced that its Board of Directors has declared regular quarterly cash dividends of $0.06 per share on the Company's Class A common shares and $0.07 per share on the Company's Class B common shares....